{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:14:39Z","timestamp":1790874879677,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003061","name":"Erasmus MC University Medical Center Rotterdam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.coi.2025.102720","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:21:10Z","timestamp":1768429270000},"page":"102720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Optimizing patient-reported outcomes for sarcoidosis"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6003-7380","authenticated-orcid":false,"given":"Vivienne","family":"Kahlmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102720_sbref1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12186088","article-title":"The symptoms of pulmonary sarcoidosis","volume":"12","author":"Judson","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2025.102720_sbref2","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102720_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00408-019-00206-7","article-title":"The burden of sarcoidosis symptoms from a patient perspective","volume":"197","author":"Voortman","year":"2019","journal-title":"Lung"},{"key":"10.1016\/j.coi.2025.102720_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00141-2018","article-title":"Sarcoidosis: patient treatment priorities","volume":"4","author":"Baughman","year":"2018","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coi.2025.102720_sbref5","article-title":"Update of the COSMIN checklist for evaluating the methodological quality of studies on measurement properties","volume":"23","author":"Terwee","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.coi.2025.102720_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","article-title":"Health, health-related quality of life, and quality of life: what is the difference?","volume":"34","author":"Karimi","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.coi.2025.102720_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-020-1116-z","article-title":"Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease","volume":"20","author":"Bae","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.coi.2025.102720_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.coi.2025.102720_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102720_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00943-2025","article-title":"Pulmonary sarcoidosis clinical trial end-points: a Delphi study","volume":"66","author":"Baughman","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/thoraxjnl-2012-201962","article-title":"The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status","volume":"68","author":"Patel","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2025.102720_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273126","article-title":"King's Sarcoidosis Questionnaire (KSQ) - validation study in Serbian speaking population of sarcoidosis patients","volume":"18","author":"Stjepanovic","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102720_bib13","first-page":"75","article-title":"Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population","volume":"33","author":"Van Manen","year":"2016","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_sbref14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1513\/AnnalsATS.202006-607OC","article-title":"Evaluating the minimal clinically important difference of the King's Sarcoidosis Questionnaire in a multicenter prospective study","volume":"18","author":"Baughman","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.coi.2025.102720_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00160-2024","article-title":"Longitudinal validation of King's Sarcoidosis Questionnaire in a prospective cohort with mild sarcoidosis","volume":"10","author":"Moller","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.coi.2025.102720_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1164\/rccm.200211-1343OC","article-title":"The Sarcoidosis Health Questionnaire: a new measure of health-related quality of life","volume":"168","author":"Cox","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102720_bib17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.coi.2025.102720_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1348\/1359107041557048","article-title":"Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS)","volume":"9","author":"De Vries","year":"2004","journal-title":"Br J Health Psychol"},{"key":"10.1016\/j.coi.2025.102720_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0022-3999(02)00392-6","article-title":"Psychometric qualities of a brief self-rated fatigue measure: the Fatigue Assessment Scale","volume":"54","author":"Michielsen","year":"2003","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.coi.2025.102720_bib20","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.rmed.2011.05.004","article-title":"Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis","volume":"105","author":"de Kleijn","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102720_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1183\/09031936.00002512","article-title":"Sarcoidosis-associated fatigue","volume":"40","author":"Drent","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2010.09.014","article-title":"The small fiber neuropathy screening list: construction and cross-validation in sarcoidosis","volume":"105","author":"Hoitsma","year":"2011","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102720_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thorax.58.4.339","article-title":"Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ)","volume":"58","author":"Birring","year":"2003","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2025.102720_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221099737","article-title":"Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough","volume":"16","author":"Nguyen","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.coi.2025.102720_bib25","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib26","first-page":"53","article-title":"Does physical training reduce fatigue in sarcoidosis?","volume":"32","author":"Marcellis","year":"2015","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000486964","article-title":"Short-term effects of a multimodal 3-week inpatient Pulmonary Rehabilitation Programme for patients with sarcoidosis: the ProKaSaRe Study","volume":"95","author":"Lingner","year":"2018","journal-title":"Respiration"},{"key":"10.1016\/j.coi.2025.102720_bib28","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(22)00387-3","article-title":"Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial","volume":"11","author":"Kahlmann","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2025.102720_sbref29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102720_bib30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40271-018-0340-6","article-title":"Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire","volume":"12","author":"Kimman","year":"2019","journal-title":"Patient"},{"key":"10.1016\/j.coi.2025.102720_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33826-4","article-title":"Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection","volume":"13","author":"Aiyegbusi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2025.102720_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.0326","article-title":"Selecting and implementing patient-reported outcome and experience measures to assess health system performance","volume":"3","author":"Bull","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.coi.2025.102720_bib33","article-title":"Health literacy, social determinants of health, and disease prevention and control","volume":"6","author":"Coughlin","year":"2020","journal-title":"J Environ Health Sci"},{"key":"10.1016\/j.coi.2025.102720_bib34","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/eurpub\/ckv043","article-title":"Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU)","volume":"25","author":"Sorensen","year":"2015","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.coi.2025.102720_bib35","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01531-2021","article-title":"The use of online visual analogue scales in idiopathic pulmonary fibrosis","volume":"59","author":"Moor","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00917-2021","article-title":"R-scale for pulmonary fibrosis: a simple, visual tool for the assessment of health-related quality of life","volume":"59","author":"Scallan","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","article-title":"Home monitoring in patients with idiopathic pulmonary fibrosis. a randomized controlled trial","volume":"202","author":"Moor","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102720_bib38","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force Report","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.coi.2025.102720_bib39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.genhosppsych.2011.05.009","article-title":"Fatigue in patients with sarcoidosis, compared with the general population","volume":"33","author":"Hinz","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.coi.2025.102720_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1164\/rccm.201410-1785OC","article-title":"Validation and important differences for the Sarcoidosis Assessment Tool. A new patient-reported outcome measure","volume":"191","author":"Judson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102720_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11136-013-0438-1","article-title":"A conceptual model of health-related quality of life in sarcoidosis","volume":"23","author":"Victorson","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.coi.2025.102720_bib42","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s11136-013-0567-6","article-title":"Development and testing of item response theory-based item banks and short forms for eye, skin and lung problems in sarcoidosis","volume":"23","author":"Victorson","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.coi.2025.102720_bib43","first-page":"333","article-title":"Determination of the smallest detectable change (SDC) and the minimal important difference (MID) for the Small Fiber Neuropathy Screening List (SFNSL) in sarcoidosis","volume":"35","author":"Voortman","year":"2018","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib44","article-title":"Validation of the Turkish version of the Sarcoidosis Health Questionnaire: a cross-sectional study","volume":"40","author":"Kavas","year":"2023","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib45","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1590\/S1806-37562015000000063","article-title":"Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia","volume":"42","author":"Mihailovic-Vucinic","year":"2016","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.coi.2025.102720_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2019.01.001","article-title":"Can the Sarcoidosis Health Questionnaire predict the long-term outcomes in Japanese sarcoidosis patients?","volume":"149","author":"Tanizawa","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.coi.2025.102720_bib47","first-page":"282","article-title":"Anxiety, its relation to symptoms severity and anxiety sensitivity in sarcoidosis","volume":"30","author":"Holas","year":"2013","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/thx.2004.022244","article-title":"Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status","volume":"60","author":"Spruit","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.coi.2025.102720_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jamda.2016.08.002","article-title":"Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients With COPD undergoing pulmonary rehabilitation: a prospective analysis","volume":"18","author":"Smid","year":"2017","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.coi.2025.102720_bib50","article-title":"Cross-cultural adaptation and validation of Leicester Cough Questionnaire in sarcoidosis: the Persian version","volume":"41","author":"Rahdar","year":"2024","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"10.1016\/j.coi.2025.102720_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-540-79842-2_16","article-title":"Clinical cough IV:\u00a0what is the minimal important difference for the Leicester Cough Questionnaire?","volume":"187","author":"Raj","year":"2009","journal-title":"Handb Exp Pharm"},{"key":"10.1016\/j.coi.2025.102720_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205308","article-title":"Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis","volume":"13","author":"Schupp","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102720_bib53","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.coi.2025.102720_bib54","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2025.102720_bib55","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s41030-023-00222-2","article-title":"Results from a phase 4, multicenter, randomized, double-blind, placebo-controlled study of Repository corticotropin injection for the treatment of pulmonary sarcoidosis","volume":"9","author":"Mirsaeidi","year":"2023","journal-title":"Pulm Ther"},{"key":"10.1016\/j.coi.2025.102720_bib57","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.coi.2025.102720_bib58","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.chest.2020.12.027","article-title":"Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis","volume":"159","author":"Drake","year":"2021","journal-title":"Chest"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:33:53Z","timestamp":1784540033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":58,"alternative-id":["S0952791525001967"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102720","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing patient-reported outcomes for sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102720","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102720"}}